Mesenchymal stem cell transplantation in Parkinson’s disease
14 February 2010
2 Comments
Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease.
“These results indicate that our protocol seems to be safe, and no serious adverse events occurred after stem-cell transplantation in PD patients. The number of patients recruited and the uncontrolled nature of the trial did not permit demonstration of effectiveness of the treatment involved. However, the results encourage future trials with more patients to demonstrate efficacy.”
Transl Res. 2010 Feb;155(2):62-70.
Advanced Neuroscience Institute, BGS-Global Hospital, Bangalore, India.
Until now, this type of treatment had only been tested in rodents. Nature Genetics
Hey this blog is great. I’m looking forward to reading more.
Leave your response!
Sponsors